Plain-English translation of NCT07285382 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing dalpiciclib, a new cancer-fighting drug, combined with letrozole (a hormone therapy you may already know about) for women with advanced breast cancer. Researchers want to find out which dose of dalpiciclib works best when paired with the hormone therapy. About 120 women will be randomly assigned to receive one of two doses of the medication, and doctors will track how well it works and how safe it is.
Many women with advanced breast cancer that is hormone-receptor-positive respond well to hormone therapy alone, but some cancers eventually become resistant to this treatment. This trial is testing whether adding a new medication to hormone therapy can help more patients and delay cancer progression.
You likely qualify if…
You likely don't qualify if…
You will take the medication (dalpiciclib plus letrozole) orally once daily at home. You will visit the study center regularly for check-ups, blood tests, and imaging scans to monitor how your cancer is responding and how your body is tolerating the treatment. You may also have small blood samples taken a few times to measure how your body processes the medication. You will continue treatment until your cancer progresses, side effects become unacceptable, or the trial ends, and you'll be followed for survival information after that.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China